Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -91.1% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100% | – | -1,778.5% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -181.4% | – | -6,220.5% | -1,621.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -152.9% | – | -14,841.1% | -1,555.6% |
| EPS Diluted | -1.21 | -8.99 | -20.15 | -26.4 |
| % Growth | 86.5% | 55.4% | 23.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |